The link between infection and cancer: Tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect

Cancer Science

Volumn 104, Issue 7, 2013, Pages 779-789

  Maeda, Hiroshi ^a  

^a SOJO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FREE RADICAL; NITRIC OXIDE; PEROXYNITRITE; SUPEROXIDE; VASCULOTROPIN; XANTHINE OXIDASE; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ANTINEOPLASTIC ACTIVITY; BACTERIAL INFECTION; BLOOD VESSEL PERMEABILITY; CARCINOGENESIS; CELL INTERACTION; CELL SURFACE; CONJUGATION; DISEASE ASSOCIATION; DNA DAMAGE; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TUMOR LEVEL; ENHANCED PERMEABILITY AND RETENTION EFFECT; ENZYME ACTIVATION; EXTRAVASATION; HUMAN; HYDROPHOBICITY; KALLIKREIN KININ SYSTEM; MACROMOLECULE; MEDIATOR; MUTATION; NANOMEDICINE; NEOPLASM; PRIORITY JOURNAL; REVIEW; TISSUE INJURY; TUMOR CELL; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CAPILLARY PERMEABILITY; FREE RADICALS; GUANOSINE; HUMANS; INFECTION; NANOMEDICINE; NEOPLASMS; NITRIC OXIDE; NITRO COMPOUNDS;

EID: 84880757123     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12152     Document Type: Review

References (116)

1. Maeda H, Konno T. Metamorphosis of neocarzinostatin to SMANCS: chemistry, pharmacology and clinical effect of the first prototype anticancer polymer therapeutic. In: Maeda H, Edo K, Ishida N, eds. Neocarzinostatin: The Past, Present, and Future of an Anticancer Drug. Tokyo: Springer-Verlag, 1997; 227-67.
2. Maeda H, Takeshita J, Kanamaru R. A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic. Int J Pept Protein Res 1979; 14: 81-7.
3. Maeda H, Ueda M, Morinaga T, Matsumoto T. Conjugation of poly (styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties. J Med Chem 1985; 28: 455-61.
4. Maeda H, Takeshita J, Kanamaru R, Sato H, Khatoh J, Sato H. Antimetastatic and antitumor activity of a derivative of neocarzinostatin: an organic solvent- and water-soluble polymer-conjugated protein. Gann 1979; 70: 601-6.
5. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-92.
6. Maeda H, Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 1989; 6: 193-210.
7. Takeshita J, Maeda H, Kanamaru R. In vitro mode of action, pharmacokinetics, and organ specificity of poly(maleic acid-styrene)-conjugated neocarzinostatin, SMANCS. Gann 1982; 73: 278-84.
8. Maeda H, Matsumoto T, Konno T, Iwai K, Ueda M. Tailor-making of protein drugs by polymer conjugation for tumor targeting: a brief review on Smancs. J Protein Chem 1984; 3: 181-93.
9. Kobayashi A, Oda T, Maeda H. Protein binding of macromolecular anticancer agent SMANCS: characterization of poly(styrene-co-maleic acid) derivatives as an albumin binding ligand. J Bioact Compat Polym 1988; 3: 319-33.
10. Oka K, Miyamoto Y, Matsumura Y et al. Enhanced intestinal absorption of a hydrophobic polymer-conjugated protein drug, smancs, in an oily formulation. Pharmaceut Res 1990; 7: 852-55.
11. Miyamoto Y, Oda T, Maeda H. Comparison of the cytotoxic effects of the high- and low-molecular-weight anticancer agents on multidrug-resistant Chinese hamster ovary cells in vitro. Cancer Res 1990; 50: 1571-75.
12. Noguchi Y, Wu J, Duncan R et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 1998; 89: 307-14.
13. Seymour LW, Miyamoto Y, Maeda H et al. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur J Cancer 1995; 31: 766-70.
14. Maeda H, Seymour LW, Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconj Chem 1992; 3: 351-62.
15. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics. J Control Release 2000; 65: 271-84.
16. 3]bradykinin in ascitic fluid from a patient with gastric cancer. J Biol Chem 1988; 263: 16051-54.
17. Maeda H, Noguchi Y, Sato K, Akaike T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn J Cancer Res 1994; 85: 331-34.
18. Maeda H, Wu J, Okamoto T, Maruo K, Akaike T. Kallikrein-kinin in infection and cancer. Immunopharmacology 1999; 43: 115-28.
19. Wu J, Akaike T, Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res 1998; 58: 159-65.
20. Wu J, Akaike T, Hayashida K, Okamoto T, Okuyama A, Maeda H. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinase. Jpn J Cancer Res 2001; 92: 439-51.
21. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41: 189-207.
22. Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Cont Release 2001; 74: 47-61.
23. Kaminishi H, Cho T, Itoh T et al. Vascular permeability enhancing activity of Porphyromonas gingivalis protease in guinea pigs. FEMS Microbiol Lett 1993; 114: 109-14.
24. Kaminishi H, Hamatake H, Cho T et al. Activation of blood clotting factors by microbial proteinases. FEMS Microbiol Lett 1994; 121: 327-32.
25. Kaminishi H, Miyaguchi H, Tamaki T et al. Degradation of humoral host defense by Candida albicans proteinase. Infect Immun 1995; 63: 984-88.
26. Matsumoto K, Yamamoto T, Kamata R, Maeda H. Pathogenesis of serratial infection: activation of the Hageman factor-prekallikrein cascade by serratial protease. J Biochem 1984; 96: 739-49.
27. Kamata R, Yamamoto T, Matsumoto K, Maeda H. A serratial protease causes vascular permeability reaction by activation of the Hageman factor-dependent pathway in guinea pigs. Infect Immun 1985; 48: 747-53.
28. Molla A, Yamamoto T, Akaike T, Miyoshi S, Maeda H. Activation of Hageman factor and prekallikrein and generation of kinin by various microbial proteinases. J Biol Chem 1989; 264: 10589-94.
29. Maeda H. Role of microbial proteases in pathogenesis. Microbiol Immunol 1996; 40: 685-99.
30. Maeda H. Microbial proteinases and pathogenesis of infection. In: Creighton TE, ed. Wiley Encyclopedia of Molecular Medicine. New York: John Wiley & Sons, 2002; 4: 2663-68.
31. Maruo K, Akaike T, Inada Y, Ohkubo I, Ono T, Maeda H. Effect of microbial and mite proteases on low and high molecular weight kininogens. J Biol Chem 1993; 268: 17711-15.
32. Matsumura Y, Kimura M, Yamamoto T, Maeda H. Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn J Cancer Res 1988; 79: 1327-34.
33. Matsumura Y, Maruo K, Kimura M, Yamamoto T, Konno T, Maeda H. Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn J Cancer Res 1991; 82: 732-41.
34. Matsumura Y, Kimura M, Kato H, Yamamoto T, Maeda H. Quantification, isolation and structural determination of bradykinin and hydroxyprolyl-bradykinin in tumor ascites. Adv Exp Med Biol 1989; 247A: 587-92.
35. Bhoola K, Ramsaroop R, Plendl J, Cassim B, Dlamini Z, Naicker S. Kallikrein and kinin receptor expression in inflammation and cancer. Biol Chem 2001; 382: 77-89.
36. Wu J, Akaike T, Hayashida K et al. Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer 2002; 98: 29-35.
37. Whalley ET, Figueroa CD, Gera L, Bhoola KD. Discovery and therapeutic potential of kinin receptor antagonists. Expert Opin Drug Discov 2012; 7: 1129-48.
38. Figueroa CD, Ehrenfeld P, Bhoola KD. Kinin receptors as targets for cancer therapy. Expert Opin Ther Targets 2012; 16: 299-312.
39. Oda T, Akaike T, Hamamoto T, Suzuki F, Hirano T, Maeda H. Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. Science 1989; 244: 974-76.
40. - generation by xanthine oxidase of pathogenesis of influenza virus infection in mice. J Clin Invest 1990; 85: 739-45.
41. Maeda H, Akaike T. Oxygen free radicals as pathogenic molecules in viral diseases. Proc Soc Exp Biol Med 1991; 198: 721-27.
42. Maeda H. Paradigm shift in microbial pathogenesis: an alternative to the Koch-Pasteur paradigm on the new millennium. In: ed. Arai S, Kurume University School of Medicine. Abstr. in the Proceedings of the 13th International Congress for Mycoplasmology; 14-19 July 2000, Fukuoka, Japan.
43. Akaike T, Noguchi Y, Ijiri S et al. Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc Natl Acad Sci USA 1996; 93: 2448-53.
44. Yoshitake J, Akaike T, Akuta T et al. Nitric oxide as an endogenous mutagen for Sendai virus without antiviral activity. J Virol 2004; 78: 8709-19.
45. Akaike T, Maeda H. Nitric oxide and virus infection. Immunology 2000; 101: 300-8.
46. Akaike T, Maeda H. Pathophysiological effects of high-output production of nitric oxide. In: Ignarro LJ, ed. Nitric Oxide. San Diego: Academic Press, 2000; 733-45.
47. Akaike T, Okamoto S, Sawa T et al. 8-Nitroguanosine formation in viral pneumonia and its implication for pathogenesis. Proc Natl Acad Sci USA 2003; 100: 685-90.
48. Akaike T, Fujii S, Kato A et al. Viral mutation accelerated by nitric oxide production during infection in vivo. FASEB J 2000; 14: 1447-54.
49. Kuwahara H, Kariu T, Fan J, Maeda H. Generation of drug-resistant mutants of Helicobacter pylori in the presence of peroxynitrite, a derivative of nitric oxide, at pathophysiological concentration. Microbiol Immunol 2009; 52: 1-7.
50. Kuwahara H, Kanazawa A, Wakamatsu D et al. Antioxidative and antimutagenic activities of 4-vinyl-2, 6-dimethoxyphenol (canolol) isolated from canola oil. J Agric Food Chem 2004; 52: 4380-87.
51. Cao X, Tsukamoto T, Seki T et al. 4-Vinyl-2, 6-dimethoxyphenol (canolol) suppresses oxidative stress and gastric carcinogenesis in Helicobacter pylori-infected carcinogen-treated Mongolian gerbils. Int J Cancer 2008; 122: 1445-54.
52. Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Moscow) 1998; 63: 1007-17.
53. Sawa T, Akaike T, Ichimori K et al. Superoxide generation mediated by 8-nitroguanosine, a highly redox-active nucleic acid derivative. Biochem Biophys Res Commun 2003; 311: 300-6.
54. Sato K, Akaike T, Kojima Y, Ando M, Nagao M, Maeda H. Evidence of direct generation of oxygen free radicals from heterocyclic amines by NADPH/cytochrome P-450 reductase in vitro. Jpn J Cancer Res 1992; 83: 1204-9.
55. Sato K, Akaike T, Suga M, Ando M, Maeda H. Generation of free radicals from neocarzinostatin mediated by NADPH/cytochrome P-450 reductase via activation of enediyne chromophore. Biochem Biophys Res Commun 1994; 205: 1716-23.
56. Kanazawa A, Sawa T, Akaike T, Maeda H. Dietary lipid peroxidation products and DNA damage in colon carcinogenesis. Eur J Lipid Sci Technol 2002; 104: 439-47.
57. Maeda H, Sato K, Akaike T. Superoxide radical generation from heterocyclic amines. In: Adamson RH, Gustafsson JA, Ito N et al. eds. Heterocyclic Amines in Cooked Foods: Possible Human Carcinogens. Proceedings of the 23rd International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo. Princeton, NJ: Princeton Scientific Publishing Co., 1995; 103-12.
58. Niles JC, Wishnok JS, Tannenbaum SR. Peroxynitrite-induced oxidation and nitration products of guanine and 8-oxoguanine: structures and mechanisms of product formation. Nitric Oxide 2006; 14: 109-21.
59. Sawa T, Ohshima H. Nitrative DNA damage in inflammation and its possible role in carcinogenesis. Nitric Oxide 2006; 14: 91-100.
60. Okada F, Nakai K, Kobayashi T et al. Inflammatory cell-mediated tumour progression and minisatellite mutation correlate with the decrease of antioxidative enzymes in murine fibrosarcoma cells. Br J Cancer 1999; 79: 377-85.
61. Okada F, Kobayashi M, Tanaka H et al. The role of nicotinamide adenine dinucleotide phosphate oxidase-derived reactive oxygen species in the acquisition of metastatic ability of tumor cells. Am J Pathol 2006; 169: 294-302.
62. Okada F, Tazawa H, Kobayashi T, Kobayashi M, Hosokawa M. Involvement of reactive nitrogen oxides for acquisition of metastatic properties of benign tumors in a model of inflammation-based tumor progression. Nitric Oxide 2006; 14: 122-9.
63. Okada F. Beyond foreign-body-induced carcinogenesis: impact of reactive oxygen species derived from inflammatory cells in tumorigenic conversion and tumor progression. Int J Cancer 2007; 121: 2364-72.
64. Shimizu T, Marusawa H, Endo Y, Chiba T. Inflammation-mediated genomic instability: roles of activation-induced cytidine deaminase in carcinogenesis. Cancer Sci 2012; 103: 1201-6.
65. Muto Y, Moriwaki H, Ninomiya M et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996; 334: 1561-67.
66. Tanaka T, Maeda M, Kohno H et al. Inhibition of azoxymethane-induced colon carcinogenesis in male F344 rats by the citrus limonoids obacunone and limonin. Carcinogenesis 2001; 22: 193-98.
67. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003; 3: 768-80.
68. Weinberg RA. The Biology of Cancer. New York: Garland Science, Taylor and Francis Group, 2007.
69. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001; 46: 169-85.
70. Li CJ, Miyamoto Y, Kojima Y, Maeda H. Augmentation of tumor delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br J Cancer 1993; 67: 975-80.
71. Kimura N, Taniguchi S, Aoki K, Baba T. Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res 1980; 40: 2060-68.
72. Skinner SA, Tutton PJM, O'Brien PE. Microvascular architecture of experimental colon tumors in the rat. Cancer Res 1990; 50: 2411-17.
73. Daruwalla J, Nikfarjam M, Greish K et al. In vitro and in vivo evaluation of tumor targeting SMA-pirarubicin micelles: survival improvement and inhibition of liver metastases. Cancer Sci 2010; 101: 1866-74.
74. Daruwalla J, Greish K, Wilson C et al. Styrene maleic acid-pirarubicin disrupts tumor microcirculation and enhances the permeability of colorectal liver metastases. J Vasc Res 2009; 46: 218-28.
75. Iwai K, Maeda H, Konno T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res 1984; 44: 2115-21.
76. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010; 21: 797-802.
77. Maeda H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B 2012; 88: 53-71.
78. Fang J, Nakamura H, Maeda H. EPR effect: the unique characteristics of tumor blood vessels for drug delivery, factors involved, its limitation and augmentation. Adv Drug Deliv Rev 2011; 63: 136-151.
79. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 2013; 65: 71-79.
80. 67 Ga-citrate and the Anger whole-body scanner, scintillation camera and tomographic scanner. J Nucl Med 1970; 11: 459-60.
81. Iwai K, Maeda H, Konno T et al. Tumor targeting by arterial administration of lipids: rabbit model with VX2 carcinoma in the liver. Anticancer Res 1987; 7: 321-8.
82. Konno T, Maeda H, Yokoyama I et al. Use of a lipid lymphographic agent, lipiodol, as a carrier of high molecular weight antitumor agent, SMANCS, for hepatocellular carcinoma. Cancer Chemother 1982; 9: 2005-15 (in Japanese).
83. Konno T, Maeda H, Iwai K et al. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 1983; 19: 1053-65.
84. Konno T, Maeda H, Iwai K et al. Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 1984; 54: 2367-74.
85. Maki S, Konno T, Maeda H. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer 1985; 56: 751-57.
86. Konno T, Maeda H. Targeting chemotherapy of hepatocellular carcinoma. In: Okuda K, Ishak KG, eds. Neoplasms of the Liver. Tokyo, Berlin, Heidelberg, New York: Springer-Verlag, 1987; 343-52.
87. Kobayashi M, Imai K, Sugihara S, Maeda H, Konno T, Yamanaka H. Tumor-targeted chemotherapy with lipid contrast medium and macromolecular anticancer drug (SMANCS) for renal cell carcinoma. Urology 1991; 37: 288-94.
88. Tsuchiya K, Uchida T, Kobayashi M. Long-term survival rate after tumor-targeted chemotherapy with the macromolecular anticancer drug SMANCS in lipid contrast medium for renal cell carcinoma: preoperative therapy for nonmetastatic cases. Urology 2000; 55: 495-500.
89. Nagamitsu A, Greish K, Maeda H. Elevating blood pressure as a strategy to increase tumor targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn J Clin Oncol 2009; 39: 756-66.
90. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release 2012; 164: 138-44.
91. Konerding MA, Miodonski AJ, Lametschwandtner A. Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc 1995; 9: 1233-44.
92. Hashizume H, Baluk P, Morikawa S et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000; 1561: 1363-80.
93. Maeda H, Fang J, Inuzuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003; 3: 319-28.
94. Maeda H, Akaike T, Wu J, Noguchi Y, Sakata Y. Bradykinin and nitric oxide in infectious disease and cancer. Immunopharmacology 1996; 33: 222-30.
95. 2 analogue beraprost sodium. J Drug Target 2003; 11: 45-52.
96. Seki T, Fang J, Maeda H. Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci 2009; 100: 2426-30.
97. Fang J, Qin H, Nakamura H, Tsukigawa K, Shin T, Maeda H. Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention (EPR) effect of solid tumor. Cancer Sci 2012; 102: 535-41.
98. Yasuda H, Yamaya M, Nakayama K et al. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small cell lung cancer. J Clin Oncol 2006; 24: 688-94.
99. Yasuda H, Nakayama K, Watanabe M et al. Nitroglycerin treatment may increase response to docetaxel and carboplatin regimen via inhibitions of hypoxia-inducible factor-1 pathway and P-glycoprotein in patients with lung adenocarcinoma. Clin Cancer Res 2006; 12: 6748-57.
100. Yasuda H, Yanagihara K, Nakayama K et al. Therapeutic applications of nitric oxide for malignant tumor in animal models and human studies. In: Bonavida B, ed. Nitric Oxide and Cancer. New York: Springer Science, 2010; 419-441.
101. Jordan BF, Misson P, Demeure R, Baudelet C, Beghein N, Gallez B. Changes in tumor oxygenation/perfusion induced by the NO donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int J Radiat Oncol Biol Phys 2000; 48: 565-70.
102. Mitchell JB, Wink DA, DeGraff W, Gamson J, Keefer LK, Krishna MC. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res 1993; 53: 5845-8.
103. Noguchi A, Takahashi T, Yamaguchi T et al. T. Enhanced tumor localization of monoclonal antibody by treatment with kininase II inhibitor and angiotensin II. Jpn J Cancer Res 1992; 83: 240-3.
104. Nakamura H, Liao L, Hitaka Y et al. Micelles of zinc protoporphyrin conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer for imaging and light-induced antitumor effects in vivo. J Control Release 2013; 165: 191-8.
105. Iyer A, Greish K, Seki T et al. Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation. J Drug Target 2007; 15: 496-506.
106. Funkhouser J. Reinventing pharma: the theranostic revolution. Curr Drug Discov 2002; 2: 17-9.
107. Kelkar S, Reineke T. Theranostics: combining imaging and therapy. Bioconjug Chem 2011; 22: 1879-1903.
108. Hatakeyama H, Akita H, Kogure K, Harashima H. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther 2007; 14: 68-77.
109. Nakamura H, Fang J, Gahininath B, Tsukigawa K, Maeda H. Intracellular uptake and behavior of two types zinc protoporphyrin (ZnPP) micelles, SMA-ZnPP and PEG-ZnPP as anticancer agents; unique intracellular disintegration of SMA micelles. J Control Release 2011; 155: 367-75.
110. Oda T, Maeda H. Binding to and internalization by cultured cells of neocarzinostatin and enhancement of its actions by conjugation with lipophilic styrene-maleic acid copolymer. Cancer Res 1987; 47: 3206-11.
111. Oda T, Sato F, Maeda H. Facilitated internalization of neocarzinostatin and its lipophilic polymer conjugate, SMANCS, into cytosol in acidic pH. J Nat Cancer Inst 1987; 9: 1205-11.
112. Oda T, Morinaga T, Maeda H. Stimulation of macrophage by polyanions and its conjugated proteins and effect on cell membrane. Proc Soc Exp Biol Med 1986; 181: 9-17.
113. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 2011; 8: 2101-41.
114. Kano M, Bae C, Iwata Y et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc Natl Acad Sci U S A 2007; 104: 3460-65.
115. Seki T, Carroll F, Illingworth S et al. Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway. J Control Release 2011; 156: 381-89.
116. Gormley AJ, Larson N, Sadekar S, Robinson R, Ray A, Ghandehari H. Guided delivery of polymer therapeutics using plasmonic photothermal therapy. Nano Today 2012; 7: 158-67.